I would not do anything differently with vaccine, knighted AstraZeneca boss says
Countries in Europe and Asia have placed age restrictions on the jab, while it has yet to be approved for use in the US.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The recently knighted head of AstraZeneca says he would not “do anything differently” despite acknowledging there had been “setbacks” with the vaccine developed with Oxford University.
Research released in June 2021 suggested Vaxzevria – more commonly known as the Oxford/AstraZeneca vaccine – is associated with slightly increased risk of some bleeding disorders.
AstraZeneca’s chief executive officer Sir Pascal Soriot, who was knighted last week for services to UK life sciences and the response to Covid-19, told the BBC the jab had saved one million lives.
When you launch yourself in something like this, which is a huge undertaking, you have to accept that you will have setbacks
“I don’t think I would do anything differently from what we did,” he added.
The French-Australian admitted there had been “setbacks” as part of the process.
“We decided to do it at no profit, we decided to partner with a network of partners around the world to scale up manufacturing,” Sir Pascal said.
“Despite the setbacks, we delivered three billion doses (of the vaccine) and saved a million lives,” he said.
“When you launch yourself in something like this, which is a huge undertaking, you have to accept that you will have setbacks.”
The Oxford/AstraZeneca Covid-19 vaccine was approved in the UK in December 2020, and jabs were initially rolled out among the older and the most vulnerable in society.
Sir Pascal, who has been chief executive at the Anglo-Swedish firm since 2012, served as chief operating officer of Roche’s pharmaceuticals division from 2010 to September 2012, and before that he was chief executive officer of Genentech, a biologics business, where he led its merger with Roche.
In late April the company said it expected revenue from its Covid-19 medicines to fall by a fifth this year as demand wanes.